Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring

Authors

Institutions

Publication Details

Journal
Annals of Clinical and Translational Neurology
Published
2026-04-21
DOI
https://doi.org/10.1002/acn3.70402
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring

Francesco Saccà, Ryan Pelto
Annals of Clinical and Translational Neurology
Complement system in diseases
article

Limitations of Complement Activity Assays as Biomarkers for Ravulizumab Therapeutic Monitoring

Francesco Saccà, Ryan Pelto
article en

Abstract

No abstract available for this paper.
Annals of Clinical and Translational Neurology
Alexion Pharma (Switzerland) (CH), University of Naples Federico II (IT)
Alexion Pharmaceuticals
Good health and well-being
Openalex Percentile: Top 12%
Complement system in diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.